Post-earnings recap
Reported
Tue, May 10, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 0.78%. However, the lack of revenue figures and future guidance leaves some uncertainty about the company's financial direction. Investors may remain focused on the company's ongoing research and development efforts as a key driver for future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | +6.93% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious optimism regarding the company's current position. They highlighted their commitment to advancing their pipeline.
Management expressed satisfaction with the EPS results despite the lack of revenue guidance.
They emphasized ongoing efforts in research and development.